Unbuckling lipodystrophy from insulin resistance and hypertension

Journal of Clinical Investigation

Volumn 114, Issue 2, 2004, Pages 163-165

  Hegele, Robert A ^a   Leff, Todd ^b  

^a ROBARTS RESEARCH INSTITUTE   (Canada)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MUTANT PROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

ADIPOSE TISSUE; GENE; GENE MUTATION; HUMAN; HYPERTENSION; INSULIN RESISTANCE; LIPODYSTROPHY; METABOLIC DISORDER; NONHUMAN; PEROXISOME PROLIFERATOR ACTIVATOR RECEPTOR GAMMA DEFICIENCY; PLEIOTROPY; PPARG GENE; PRIORITY JOURNAL; PROTEIN DEFICIENCY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW;

ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; HYPERTENSION; INSULIN RESISTANCE; LIPODYSTROPHY; MICE; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RENIN-ANGIOTENSIN SYSTEM; TRANSCRIPTION FACTORS;

EID: 4043072234     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI200422382     Document Type: Review

References (16)

1. Laaksonen, D.E., et al. 2002. Metabolic syndrome and development of diabetes mellitus: application and validation of recently suggested definitions of the metabolic syndrome in a prospective cohort study. Am. J. Epidemiol. 156:1070-1077.
2. Lakka, H.M., et al. 2002. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA. 288:2709-2716.
3. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. 2001. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. 285:2486-2497.
4. Marx, N., Duez, H., Fruchart, J.C., and Staels, B. 2004. Peroxisome proliferator-activated receptors and atherogenesis: regulators of gene expression in vascular cells. Circ. Res. 94:1168-1178.
5. Stumvoll, M., and Haring, H.U. 2002. Glitazones: clinical effects and molecular mechanisms. Ann. Med. 34:217-224.
6. Hegele, R.A. 2003. Monogenic forms of insulin resistance: apertures that expose the common metabolic syndrome. Trends Endocrinol. Metab. 14:371-377.
7. Tsai, Y.-S., et al. 2004. Hypertension and abnormal fat distribution but not insulin resistance in mice with P465L PPARγ. J. Clin. Invest. 114:240-249. doi:10.1172/JC1200420964.
8. Barroso, I., et al. 1999. Dominant negative mutations in human PPARgamma associated with severe insulin resistance, diabetes mellitus and hypertension. Nature. 402:880-883.
9. Agarwal, A.K., and Garg, A. 2002. A novel heterozygous mutation in peroxisome proliferator-activated receptor-gamma gene in a patient with familial partial lipodystrophy. J. Clin. Endocrinol. Metab. 87:408-411.
10. Hegele, R.A., et al. 2002. PPARG F388L, a transactivation-deficient mutant, in familial partial lipodys trophy. Diabetes. 51:3586-3590.
11. Savage, D.B., et al. 2003. Human metabolic syndrome resulting from dominant-negative mutations in the nuclear receptor peroxisome proliferator-activated receptor-gamma. Diabetes. 52:910-917.
12. Hegele, R.A., et al. 2003. Elevated serum C-reactive protein and free fatty acids among nondiabetic carriers of missense mutations in the gene encoding lamin A/C (LMNA) with partial lipodystrophy. Arterioscler. Thromb. Vasc. Biol. 23:111-116.
13. Hegele, R.A. 2004. Phenomics, lipodystrophy and the metabolic syndrome. Trends Cardiovasc. Med. 14:133-137.
14. Dobrian, A.D., Schriver, S.D., Khraibi, A.A., and Prewitt, R.L. 2004. Pioglitazone prevents hypertension and reduces oxidative stress in diet-induced obesity. Hypertension. 43:48-56.
15. Miles, P.D., Barak, Y., He, W., Evans, R.M., and Olefsky, J.M. 2000. Improved insulin-sensitivity in mice heterozygous for PPAR-gamma deficiency. J. Clin. Invest. 105:287-292.
16. Engeli, S., et al. 2003. The adipose-tissue reninangiotensin-aldosterone system: role in the metabolic syndrome? Int. J. Biochem. Cell Biol. 35:807-825.